How would you taper tocilizumab in a patient treated with the GIACTA 26 week steroid and tocilizumab protocol?  

This is a very important question that should be high on the research agenda in GCA in the coming years. Several studies investigating the risk of relapse in GCA have yielded relapse rates ranging from the 30s-70s%. While these studies have significant limitations, it's reasonable to assume that the...

Here is another interesting reflection on stopping therapy in GCA by Dr. David Liew, incorporating data from the SELECT-GCA extension data (for upadacitinib) and METOGiA trial presented at ACR 2025: Liew, RheumNow 2025.